<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651156</url>
  </required_header>
  <id_info>
    <org_study_id>156-12-809-01</org_study_id>
    <nct_id>NCT01651156</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema</brief_title>
  <official_title>Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Phase 3 Study to Evaluate the Efficacy and Safety of Tolvaptan in the Treatment of Patients With Cardiac Edema Based on the Conventional Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, multicenter, placebo-controlled, parallel study to evaluate the&#xD;
      efficacy and safety of Tolvaptan in the treatment of patients with cardiac edema (body fluid&#xD;
      retention caused by congestive heart failure) based on the conventional therapy.&#xD;
&#xD;
      To evaluate the efficacy and safety of Tolvaptan 15 mg on congestive heart failure patients&#xD;
      with body fluid retention after current diuretic treatment, after continuous treatment of 7&#xD;
      days' oral Tolvaptan 15mg or placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  A randomized, double-blind, multicenter, placebo-controlled, parallel study&#xD;
&#xD;
        -  Study population: The congestive heart failure patients with body fluid retention after&#xD;
           received current diuretics therapy&#xD;
&#xD;
        -  Number of patients: Patients will be randomly assigned to Tolvaptan and placebo group in&#xD;
           1:1 ratio, 120 patients in each group, 240 patients in total&#xD;
&#xD;
        -  Group assignment method: Tolvaptan 15 mg group: conventional therapy + Tolvaptan 15 mg&#xD;
           Placebo group: conventional therapy + placebo&#xD;
&#xD;
        -  Administration and dosage of the study drug: Once daily, 1 tablet be taken orally after&#xD;
           breakfast, for successive 7 days&#xD;
&#xD;
        -  Study period:&#xD;
&#xD;
        -  Screening period (4 days in minimum, 7 days in maximum), including:&#xD;
&#xD;
      Screening period: from the time the informed consent form is signed to Day -4 Observation&#xD;
      period: 3 days before drug administration&#xD;
&#xD;
        -  Treatment period: 7 days&#xD;
&#xD;
        -  Follow up visits: Day 8 (efficacy evaluation day) and Day 7 (+3) after the last dosing&#xD;
&#xD;
        -  Post treatment survey: Day 14 (+3) after the last dosing&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>body weight (change from baseline)</measure>
    <time_frame>screening day, Day-3, Day-2, Day-1, Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day(7+3)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight (percent change from baseline)</measure>
    <time_frame>screening day, Day-3, Day-2, Day-1, Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day(7+3)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Cardiac Edema</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Frequency: once per day Duration: 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tolvaptan tablet Frequency: once per day Duration: 7days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>oral taken</description>
    <arm_group_label>Tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients treated with one of the oral diuretic therapy standards （include the patients&#xD;
             who will be treated with one of the oral diuretic therapy standards from the beginning&#xD;
             of the observation period）:&#xD;
&#xD;
               1. Only 40 mg/day furosemide taken orally or other oral loop diuretics equivalent to&#xD;
                  40 mg/day furosemide note 1)&#xD;
&#xD;
               2. Combination treatment of oral loop diuretics and thiazide diuretics (no dosage&#xD;
                  limitation)&#xD;
&#xD;
               3. Combination treatment of oral loop diuretics and aldosterone antagonists (no&#xD;
                  dosage limitation)&#xD;
&#xD;
          -  Because of the existence of excess body fluid retention, the congestive heart failure&#xD;
             patient has at least one of these symptoms (the lower extremity edema, pulmonary&#xD;
             congestion note 2), or jugular vein engorgement).&#xD;
&#xD;
          -  20-85 years of age (inclusive) at the time of signing the informed consent document.&#xD;
&#xD;
          -  Gender: male or female.&#xD;
&#xD;
          -  Inpatients or patient who would be hospitalized from one day before the observation&#xD;
             period to the end of efficacy evaluation examination after the last dosing (from Day&#xD;
             -4 to the end of efficacy evaluation examination after the last dosing).&#xD;
&#xD;
          -  Patient who have signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients equipped with circulatory assistant device.&#xD;
&#xD;
          -  Patients with any of following diseases, complications or symptoms:&#xD;
&#xD;
               1. Suspected decreased blood volume&#xD;
&#xD;
               2. Obstructive hypertrophic cardiomyopathy&#xD;
&#xD;
               3. Severe aortic stenosis&#xD;
&#xD;
               4. Hepatic coma&#xD;
&#xD;
          -  Patients with history of acute myocardial infarction within 30 days prior to&#xD;
             screening.&#xD;
&#xD;
          -  Patients with diagnosed active myocarditis or amyloid cardiomyopathy.&#xD;
&#xD;
          -  Patients with the following diseases, complications or symptoms:&#xD;
&#xD;
               1. Poorly controlled diabetes with a fasting glucose more than 220 mg/dL (or 12.21&#xD;
                  mmol/L)&#xD;
&#xD;
               2. Anuria&#xD;
&#xD;
               3. Dysuria caused by urethral stricture, calculus or tumor&#xD;
&#xD;
          -  Patients with the following medical history of:&#xD;
&#xD;
               1. Sustained ventricular tachycardia or ventricular fibrillation within 30 days&#xD;
                  prior to screening&#xD;
&#xD;
               2. History of cerebrovascular accident within the past 30 days&#xD;
&#xD;
               3. Past allergy or hypersensitive reactions to benzodiazepines (e.g. mozavaptan&#xD;
                  hydrochloride or benazepril hydrochloride)&#xD;
&#xD;
          -  Obese patients whose body mass index (BMI = body weight (kg) / height (m)2 ) is more&#xD;
             than 35.&#xD;
&#xD;
          -  Patients with systolic pressure below 90 mmHg in supine position.&#xD;
&#xD;
          -  Patients with any of the following abnormal laboratory test parameters:&#xD;
&#xD;
               1. Total bilirubin &gt; 2.5 times the upper limits of normal value&#xD;
&#xD;
               2. Serum creatine &gt; 2.5 times the upper limits of normal value&#xD;
&#xD;
               3. Serum Na+ &gt; 145 mmol/L (or higher than the upper limits of normal value)&#xD;
&#xD;
               4. Serum K+ &gt; 5.5 mmol/L&#xD;
&#xD;
          -  Patients who unable to take medicine orally.&#xD;
&#xD;
          -  Female patients who are pregnant, breast-feeding, at childbearing ages, or with&#xD;
             pregnancy plan.&#xD;
&#xD;
          -  Patients who participated in clinical trials of other medicine and took other study&#xD;
             drugs within 30 days prior to sign the informed consent form.&#xD;
&#xD;
          -  Patients who participated in the clinical trial of Tolvaptan and took Tolvaptan&#xD;
             previously.&#xD;
&#xD;
          -  Patients who have received approved Tolvaptan tablets (Trade name: Samsca) previously.&#xD;
&#xD;
          -  Except for the above, patients who were unsuitable to participate in this trial in the&#xD;
             investigator's opinion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhang Jian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Cardiovascular hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>December 25, 2013</last_update_submitted>
  <last_update_submitted_qc>December 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema, Cardiac</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

